Anti-inflammatory Therapeutics Market in Asia-Pacific See Huge Growth $40.5 Billion by 2032 With CAGR of 5.4% : AMR

The Asia-Pacific anti-inflammatory therapeutics market growth is driven by increase in R&D activities for novel medication development.

WILMINGTON, DELAWARE, UNITED STATES, July 10, 2024 /EINPresswire.com/ -- According to the report, the Asia-Pacific anti-inflammatory therapeutics market
was estimated at in $𝟐𝟑.𝟖 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 2022, and is anticipated to hit by 2032, $𝟒𝟎.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 registering a 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟒% from 2023 to 2033.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐨𝐧 𝐀𝐬𝐢𝐚-𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐀𝐧𝐭𝐢-𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟑𝟐 -
https://www.alliedmarketresearch.com/request-sample/1175

𝐏𝐫𝐢𝐦𝐞 𝐝𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐧𝐭𝐬 𝐨𝐟 𝐠𝐫𝐨𝐰𝐭𝐡

Increase in the prevalence of inflammatory diseases such as arthritis, inflammatory bowel diseases and others and surge use of corticosteroids to treat various inflammatory diseases drive the growth of the Asia-Pacific anti-inflammatory therapeutics market. However, side effects associated with the corticosteroids and NSAIDs are hampering the Asia-Pacific anti-inflammatory therapeutics market growth. On the contrary, increase in research and development activities for the development of novel anti-inflammatory therapeutics is expected to offer remunerative opportunity for expansion of the Asia-Pacific anti-inflammatory therapeutics market during the forecast period.

𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 & 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:

𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗣𝗲𝗿𝗶𝗼𝗱- 𝟮𝟬𝟮𝟯–𝟮𝟬𝟯𝟮
𝗕𝗮𝘀𝗲 𝗬𝗲𝗮𝗿- 𝟮𝟬𝟮𝟮
𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗶𝘇𝗲 𝗶𝗻 𝟮𝟬𝟮𝟮- $𝟮𝟯.𝟴 𝗯𝗶𝗹𝗹𝗶𝗼𝗻
𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗶𝘇𝗲 𝗶𝗻 𝟮𝟬𝟯𝟮- $𝟰𝟬.𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻
𝗖𝗔𝗚𝗥- 𝟱.𝟰𝟬%
𝗡𝗼. 𝗼𝗳 𝗣𝗮𝗴𝗲𝘀 𝗶𝗻 𝗥𝗲𝗽𝗼𝗿𝘁- 𝟮𝟬𝟮

𝐑𝐞𝐜𝐞𝐬𝐬𝐢𝐨𝐧 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨

▪️ In the economic recession, the anti-inflammatory therapeutics market is driven by increase in prevalence of inflammatory diseases.
▪️ However, fluctuations in the demand for pharmaceuticals including anti-inflammatory therapeutics as companies adjust their spending priorities impact the anti-inflammatory therapeutics market growth.

𝐖𝐚𝐧𝐭 𝐭𝐨 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐨𝐫𝐞, 𝐂𝐨𝐧𝐧𝐞𝐜𝐭 𝐭𝐨 𝐨𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 -
https://www.alliedmarketresearch.com/connect-to-analyst/1175

𝐓𝐡𝐞 𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on indication, the arthritis segment accounted for the largest share in 2022, and is the fastest growing segment during the forecast period, contributing to nearly two-fifths of the Asia-Pacific anti-inflammatory therapeutics market revenue, owing to, increase in prevalence of arthritis and surge in number of people taking treatment for arthritis.

𝐓𝐡𝐞 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on drug class, the biologics segment held the highest market share in 2022, and is the fastest growing segment during the forecast period, accounting for more than two-fifths of the anti-inflammatory therapeutics market revenue, owing to increase in use of biologics for the treatment of arthritis and other inflammatory diseases.

𝐓𝐡𝐞 𝐝𝐫𝐮𝐠 𝐬𝐭𝐨𝐫𝐞𝐬 𝐚𝐧𝐝 𝐫𝐞𝐭𝐚𝐢𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on distribution channel, the drug stores and retail pharmacies segment held the highest market share in 2022, and is the fastest growing segment during the forecast period, accounting for nearly two-fifths of the Asia-Pacific anti-inflammatory therapeutics market revenue, owing to increase in sell of anti-inflammatory drugs through retail pharmacy stores and rise in number of people suffering from various inflammatory diseases.

𝐅𝐨𝐫 𝐏𝐫𝐨𝐜𝐮𝐫𝐞𝐦𝐞𝐧𝐭 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 -
https://www.alliedmarketresearch.com/purchase-enquiry/1175

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: -

Abbvie Inc.
Amgen Inc.
Pfizer Inc.
GalaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Johnson and Johnson
Novartis AG
Eli Lilly and Company
Bayer AG
AstraZeneca plc

The report provides a detailed analysis of these key players of the Asia-Pacific anti-inflammatory therapeutics market. These players have adopted strategies such as, product launch and product approval to increase their market share and maintain dominant shares in different countries. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X